CR7264A - Formulaciones de sucralosa para disimular sabores desagradables - Google Patents

Formulaciones de sucralosa para disimular sabores desagradables

Info

Publication number
CR7264A
CR7264A CR7264A CR7264A CR7264A CR 7264 A CR7264 A CR 7264A CR 7264 A CR7264 A CR 7264A CR 7264 A CR7264 A CR 7264A CR 7264 A CR7264 A CR 7264A
Authority
CR
Costa Rica
Prior art keywords
disagulable
flavors
hidden
medicines
directed
Prior art date
Application number
CR7264A
Other languages
English (en)
Inventor
Jaeger David
Dickerson Jay
Trimmer Annabelle
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23195896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7264A publication Critical patent/CR7264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta dirigida a una base excipiente liquida farmaceuticamente aceptable para disimular sabor para la administracion de una cantidad relativamente amplia de medicinas con sabor desagradable. Mas particularmente, se provoca aumentar la dulzura y tener el efecto de disimular el sabor por la adicion de sucralosa a la base excipiente con el mantenimiento de un pH de 2 a 5. La invencion ademas esta dirigida a composiciones medicinales que comprenden la base excipiente liquida y medicinas con sabor desagradable. Ademas, la invencion se dirige a un metodo para disimular el sabor desagradable de medicinas a traves de su incorporacion a las bases excipientes liquidas.
CR7264A 2001-07-31 2004-02-27 Formulaciones de sucralosa para disimular sabores desagradables CR7264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30891201P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
CR7264A true CR7264A (es) 2004-05-17

Family

ID=23195896

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7264A CR7264A (es) 2001-07-31 2004-02-27 Formulaciones de sucralosa para disimular sabores desagradables

Country Status (13)

Country Link
US (2) US20060121066A1 (es)
EP (1) EP1411955A4 (es)
JP (2) JP2004538309A (es)
AU (1) AU2002324579B2 (es)
BR (1) BR0211794A (es)
CA (1) CA2455939C (es)
CL (1) CL2004000208A1 (es)
CO (1) CO5560580A2 (es)
CR (1) CR7264A (es)
EC (1) ECSP044995A (es)
MX (1) MXPA04001026A (es)
NZ (1) NZ530889A (es)
WO (1) WO2003011306A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
JP2013053136A (ja) * 2011-08-09 2013-03-21 Taisho Pharmaceutical Co Ltd 内服液剤
WO2013084090A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
US20150056288A1 (en) 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3069733B1 (en) * 2013-11-13 2022-08-10 National Defense Education and Research Foundation New acetaminophen compound composition without side effect to liver
JP6565334B2 (ja) * 2014-06-18 2019-08-28 大正製薬株式会社 固形製剤
CN105640956B (zh) * 2014-11-14 2018-09-14 澳美制药厂有限公司 不含防腐剂的复方磷酸可待因组合口服液及其制备方法
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20160317497A1 (en) * 2015-05-01 2016-11-03 Trinity Ent And Facial Aesthetics Flavored analgesic and decongestant spray
JP6794758B2 (ja) * 2015-10-21 2020-12-02 大正製薬株式会社 経口液体医薬組成物
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4293009A3 (en) 2015-12-22 2024-02-21 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US20210069127A1 (en) * 2017-03-27 2021-03-11 DXM Pharmaceuticals, Inc. Multi-Dose Concentrated Liquid Diphenhydramine HCl Compositions and Packaged Multi-Dose Liquid Diphenhydramine HCl Formulations
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN112439072A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种掩味组合物及其制备方法、用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5374569A (en) * 1992-09-21 1994-12-20 Siliconix Incorporated Method for forming a BiCDMOS
EP0620001A1 (en) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
CZ210496A3 (en) * 1994-01-24 1996-12-11 Procter & Gamble Method improving solution process of difficult-to dissolve pharmaceutically active compounds
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
JP2000135055A (ja) * 1998-10-29 2000-05-16 Sanei Gen Ffi Inc 乳感の向上した乳含有製品
EP1216044A1 (en) * 1999-09-29 2002-06-26 The Procter & Gamble Company Compositions having improved stability
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen

Also Published As

Publication number Publication date
JP2010090142A (ja) 2010-04-22
BR0211794A (pt) 2004-11-03
US20110136851A1 (en) 2011-06-09
JP2004538309A (ja) 2004-12-24
US20060121066A1 (en) 2006-06-08
ECSP044995A (es) 2004-04-28
AU2002324579B2 (en) 2007-11-15
CA2455939C (en) 2011-03-22
EP1411955A4 (en) 2006-07-05
CL2004000208A1 (es) 2005-03-18
CA2455939A1 (en) 2003-02-13
EP1411955A1 (en) 2004-04-28
MXPA04001026A (es) 2005-06-20
WO2003011306A1 (en) 2003-02-13
CO5560580A2 (es) 2005-09-30
NZ530889A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
CR7264A (es) Formulaciones de sucralosa para disimular sabores desagradables
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
CN110382007A (zh) 具有恢复的环境效应的组合物的快速和受控递送
WO2002032376A3 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
BR0308927A (pt) Comprimido mastigável de sabor agradável
TW200640486A (en) Composition
MX344036B (es) Composiciones que comprenden azelastina y metodos de uso de la misma.
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
SE0102276D0 (sv) Device and method for the administration of a medicament
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
WO2006063111A3 (en) Pharmaceutical formulations cytidine analogs and derivatives
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
WO2005065646A3 (en) Novel drug compositions and dosage forms
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
EP1161956A4 (en) DRUG COMPOSITIONS
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
US10028967B2 (en) Medicament
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate